COPD researchers are pivoting toward disease-modifying therapies that target newly understood mechanisms including cellular senescence, neuro-immune crosstalk, and metabolic reprogramming. The review highlights senolytics (drugs that clear senescent cells) and nucleic acid-based therapies as particularly promising approaches, alongside advanced lung-targeted nanocarrier delivery systems. This represents a significant departure from current COPD management, which relies primarily on bronchodilators and corticosteroids that provide symptom relief without halting disease progression. The senescence connection is particularly intriguing given COPD's age-related prevalence and the growing body of longevity research showing cellular senescence drives multiple age-related diseases. However, translating these mechanistic insights into clinical success remains challenging - COPD's heterogeneous nature and the lung's complex repair mechanisms have historically made drug development difficult. The emphasis on precision medicine approaches and biomarker-guided patient stratification suggests researchers are learning from past failures. While promising, these next-generation therapies will need to demonstrate not just safety and efficacy, but actual structural lung repair - something no current COPD treatment achieves.